Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) rose 3.9% during mid-day trading on Tuesday . The company traded as high as $7.00 and last traded at $6.74, with a volume of 632,392 shares changing hands. The stock had previously closed at $6.49.

RPTP has been the topic of a number of analyst reports. Leerink Swann reiterated an “outperform” rating and set a $11.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, April 12th. Oppenheimer Holdings Inc. reiterated a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a research note on Monday, April 11th. Citigroup Inc. lowered shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $6.00 to $8.00 in a research note on Monday. Cowen and Company reiterated a “buy” rating and set a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, April 17th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. Raptor Pharmaceutical Corp. has a consensus rating of “Hold” and a consensus target price of $7.17.

The company has a 50-day moving average price of $5.80 and a 200-day moving average price of $4.91. The firm’s market capitalization is $573.26 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company earned $32.05 million during the quarter, compared to analyst estimates of $28.52 million. The firm’s revenue for the quarter was up 37.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) earnings per share. On average, analysts forecast that Raptor Pharmaceutical Corp. will post ($0.95) EPS for the current year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Globeflex Capital L P increased its stake in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 116.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,787 shares of the company’s stock after buying an additional 113,016 shares during the period. Globeflex Capital L P owned about 0.25% of Raptor Pharmaceutical Corp. worth $1,091,000 at the end of the most recent quarter.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.